Cargando…
The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial)
BACKGROUND: Sepsis is still a common critical disease with high morbidity and mortality in intensive care unit. Despite published guidelines for sepsis, development of antibiotic therapy and advanced organ support technologies, the mortality of sepsis patients is still 25% or more. It is necessary t...
Autores principales: | Zhou, Zhigang, Feng, Tienan, Xie, Yun, Huang, Peijie, Xie, Hui, Tian, Rui, Qian, Biyun, Wang, Ruilan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729060/ https://www.ncbi.nlm.nih.gov/pubmed/31492102 http://dx.doi.org/10.1186/s12879-019-4388-2 |
Ejemplares similares
-
A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
por: Zhu, Qiuhua, et al.
Publicado: (2021) -
Management of COVID-19-related immune thrombocytopenia by rhTPO
por: Zhang, Xuzhao, et al.
Publicado: (2021) -
rhTPO Ameliorates Radiation-Induced Long-Term Hematopoietic Stem Cell Injury in Mice
por: Luan, Hao, et al.
Publicado: (2023) -
A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer
por: Xu, Yunhua, et al.
Publicado: (2018) -
rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma
por: Zhu, Jun, et al.
Publicado: (2019)